SG Americas Securities LLC Has $126,000 Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)

SG Americas Securities LLC decreased its stake in BeiGene, Ltd. (NASDAQ:BGNE) by 19.4% in the fourth quarter, HoldingsChannel reports. The firm owned 698 shares of the company’s stock after selling 168 shares during the period. SG Americas Securities LLC’s holdings in BeiGene were worth $126,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. boosted its position in BeiGene by 26.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 244 shares of the company’s stock worth $54,000 after acquiring an additional 51 shares during the period. Toronto Dominion Bank raised its stake in shares of BeiGene by 166.4% in the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock valued at $60,000 after acquiring an additional 208 shares in the last quarter. Knights of Columbus Asset Advisors LLC raised its stake in shares of BeiGene by 20.5% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock valued at $80,000 after acquiring an additional 76 shares in the last quarter. 1832 Asset Management L.P. raised its stake in shares of BeiGene by 1,279.3% in the 4th quarter. 1832 Asset Management L.P. now owns 800 shares of the company’s stock valued at $176,000 after acquiring an additional 742 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of BeiGene by 1,058.4% in the 2nd quarter. Barclays PLC now owns 1,031 shares of the company’s stock valued at $184,000 after acquiring an additional 942 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Price Performance

Shares of NASDAQ:BGNE opened at $131.86 on Thursday. BeiGene, Ltd. has a 1-year low of $131.28 and a 1-year high of $270.57. The firm has a market capitalization of $12.61 billion, a PE ratio of -15.51 and a beta of 0.61. The business’s 50 day moving average is $155.97 and its 200-day moving average is $169.12. The company has a current ratio of 2.32, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Monday, February 26th. The company reported ($3.53) EPS for the quarter, beating the consensus estimate of ($3.61) by $0.08. The business had revenue of $634.40 million for the quarter, compared to analyst estimates of $632.52 million. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. BeiGene’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($4.29) EPS. Sell-side analysts predict that BeiGene, Ltd. will post -8.87 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BGNE shares. Bank of America cut their price objective on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research note on Monday, April 8th. Sanford C. Bernstein dropped their price target on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research report on Wednesday, March 27th. Guggenheim dropped their price target on BeiGene from $350.00 to $345.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. lifted their price target on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $251.70.

Insider Activity at BeiGene

In related news, CEO John Oyler sold 37,668 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total value of $6,178,305.36. Following the sale, the chief executive officer now owns 12,332 shares of the company’s stock, valued at approximately $2,022,694.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO John Oyler sold 37,668 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total value of $6,178,305.36. Following the sale, the chief executive officer now owns 12,332 shares of the company’s stock, valued at approximately $2,022,694.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Julia Aijun Wang sold 397 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The disclosure for this sale can be found here. Insiders have sold a total of 64,781 shares of company stock valued at $10,222,381 in the last 90 days. 7.40% of the stock is owned by corporate insiders.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.